TransCon CNP

Designed for continuous CNP exposure to rebalance bone growth in skeletal disorders

Designed for continuous CNP exposure to rebalance bone growth in skeletal disorders

Vector-Smart-Object-copy

TransCon technology has extended exposure of CNP from 2.5 minutes to 120 hours - unlocking its therapeutic potential to pursue a new frontier of growth biology.

Explore

You are about to access www.ascendispharma.us, which includes information intended for U.S. residents only. Click below to confirm.

Are you a U.S. resident?

If so, please confirm below to proceed to our U.S. website. If not, continue to our global website.

You are about to access www.ascendispharma.us, which includes information intended for U.S. residents only. Click below to confirm.